General
Preferred name
CLEVUDINE
Synonyms
L-FMAU ()
Levovir ()
Levovir,L-FMAU ()
Clevudina ()
P&D ID
PD071621
CAS
163252-36-6
Tags
available
drug
prodrug
Drug indication
chronic hepatitis B virus infection
Hepatitis B virus infection
Drug Status
approved
investigational
Max Phase
3.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PRICE 29
DESCRIPTION Clevudine (Levovir) is a synthetic pyrimidine analogue with activity against hepatitis B virus (HBV). Intracellularly, clevudine is phosphorylated to its active metabolites, clevudine monophosphate and triphosphate. The triphosphate metabolite competes with thymidine for incorporation into viral DNA, thereby causing DNA chain termination and inhibiting the function of HBV DNA polymerase (reverse transcriptase). Clevudine has a long half-life and shows significant reduction of covalently closed circular DNA (cccDNA), therefore the patient is less likely to have a relapse after treatment is discontinued. (TargetMol Bioactive Compound Library)
Cell lines
0
Organisms
1
Compound Sets
10
Cayman Chemical Bioactives
ChEMBL Drugs
Drug Repurposing Hub
DrugBank
DrugCentral
DrugCentral Approved Drugs
DrugMAP
ReFrame library
Selleckchem Bioactive Compound Library
TargetMol Bioactive Compound Library
External IDs
64
Properties
(calculated by RDKit )
Molecular Weight
260.08
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
3
Rotatable Bonds
2
Ring Count
2
Aromatic Ring Count
1
cLogP
-1.57
TPSA
104.55
Fraction CSP3
0.6
Chiral centers
4.0
Largest ring
6.0
QED
0.6
Structural alerts
0
No structural alerts detected
Custom attributes
(extracted from source data)
Target
DNA polymerase
DNA/RNA Synthesis
HBV
RNA polymerase
Indication
hepatitis B
MOA
DNA polymerase inhibitor
Pathway
Cell Cycle/Checkpoint
DNA Damage/DNA Repair
Microbiology/virology
Source data